POOLBEG PHARMA

Company Presentation

December 2025

AIM: POLB

Disclaimer

The contents of this presentation and the information which you are given at the time of the presentation have not been approved by an authorised person within the meaning of the Financial Services and Markets Act 2000 (the "Act"). Reliance on this presentation for the purpose of engaging in investment activity may expose an individual to a significant risk of losing all of the property or other assets invested. This presentation does not constitute or form part of any offer for sale or subscription or solicitation of any offer to buy or subscribe for any securities in Poolbeg Pharma plc (the "Company") nor shall it form the basis of or be relied on in connection with any contract or commitment whatsoever. No reliance may be placed for any purpose whatsoever on the information contained in this presentation and/or opinions therein. This presentation is exempt from the general restriction (in section 21 of the Act) on the communication of invitations or inducements to engage in investment activity on the grounds that it is made to: (a) persons who have professional experience in matters relating to investments who fall within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order"); or (b) high net worth entities and other persons to whom it may otherwise lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as "relevant persons"). Any person (whether a relevant person or otherwise) is recommended to seek their own independent financial advice from a person authorised for the purposes of the Act before engaging in any investment activity involving the Company's securities. Any recipient who is not a relevant person should return this presentation to the Company's registered office and should not act upon it. By accepting this presentation and not immediately returning it, each recipient warrants, represents, acknowledges and agrees that it is a relevant person.

This presentation does not constitute or form part of any offer or invitation or inducement to sell, issue, purchase or subscribe for (or any solicitation of any offer to purchase or subscribe for) the Company's securities in the UK, US or any other jurisdiction and its distribution does not form the basis of, and should not be relied on in connection with, any contract or investment decision in relation thereto nor does it constitute a recommendation regarding the Company's securities by the Company or its advisers and agents. Nothing in the presentation shall form the basis of any contract or commitment whatsoever. The distribution of this presentation outside the UK may be restricted by law and therefore persons outside the UK into whose possession this presentation comes should inform themselves about and observe any such restrictions as to the distribution of this presentation. The Company has not registered, and does not intend to register, any securities under the US Securities Act of 1933, as amended or to conduct a public offering of any securities in the US. The securities of the Company have not been approved or disapproved by the U.S. Securities and Exchange Commission or by any U.S. state regulatory authority, nor have any of the foregoing passed on the accuracy or adequacy of this presentation. Any representation to the contrary is a criminal offence.

This presentation contains "forward-looking" statements, beliefs, estimates, forecasts and opinions, including statements with respect to the business, financial condition, results of operations and plans of the Company and its group ("Group"), which constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements involve known and unknown risks and uncertainties, many of which are beyond the Company's control and all of which are based on the current beliefs and expectations of the directors about future events. Recipients should note that past performance is not necessarily an indication of future performance and no assurance can be given that they will be attained. Forward-looking statements are sometimes identified by the use of forward-looking terminology such as "believes", "expects", "budgets", "schedules", "forecasts", "may", "might", "will", "will be taken", "occur", "be achieved", "would", "may", "will", "could", "should", "shall", "risk", "intends", "estimates", "aims", "plans", "predicts", "continues", "assumes", "positioned" or "anticipates" or the negative thereof, other variations thereon or comparable terminology or by discussions of strategy, plans, objectives, goals, future events or intentions. These forward-looking statements may and often do differ materially from actual results.

The significant risks related to the Company's business which could cause the Company's actual results and developments to differ materially from those forward-looking statements appear in a number of places throughout this presentation and include statements regarding the intentions, beliefs or current expectations of the directors of the Company with respect to future events and are subject to risks relating to future events and other risks, uncertainties and assumptions relating to the Group's business, concerning, amongst other things, the results of operations, financial condition, prospects, growth and strategies of the Group and the industry in which it operates. No one will publicly update or revise any forward-looking statements or any other information contained herein, either as a result of new information, future events or otherwise.

In considering the performance information contained herein, recipients should bear in mind that past performance is not necessarily indicative of future results, and there can be no assurance unrealised return projections will be met. Certain of the past performance information presented herein may not be representative of all transactions of a given type. Actual events could differ materially from those projected herein and depend on a number of factors, including the success of the Group's development strategies, the successful and timely completion of clinical studies, securing satisfactory licensing agreements for products, the ability of the Group to obtain additional financing for its operations and the market conditions affecting the availability and terms of such finances. The forward-looking statements included in this presentation are expressly qualified by the cautionary statements herein.

The Company reports under International Financial Reporting Standards as issued by the International Accounting Standards Board. Where foreign currency equivalents have been provided for convenience in this presentation, the exchange rates applied are those used in the relevant financial statements from which the figures have been extracted. This presentation is confidential and is being supplied to each recipient of it solely for its information. While this presentation has been prepared in good faith, no representation, warranty, assurance or undertaking (express or implied) is or will be made, and no responsibility or liability is or will be accepted by the Company or by its officers, employees or agents in relation to the adequacy, accuracy, completeness or reasonableness of this presentation, or of any other information (whether written or oral), notice or document supplied or otherwise made available to any recipient. This presentation has been prepared to assist a recipient in making its own evaluations and does not purport to be all-inclusive or contain all of the information a recipient may desire.

Forward Looking Statements

This presentation may contain forward-looking statements containing the words "expect", "anticipate", "intends", "plan", "estimate", "aim", "forecast", "project" and similar expressions (or their negative) identify certain of these forward-looking statements. The forward-looking statements in this communication are based on numerous assumptions and Poolbeg's present and future business strategies and the environment in which Poolbeg expects to operate in the future. Forward-looking statements involve inherent known and unknown risks, uncertainties and contingencies because they relate to events and depend on circumstances that may or may not occur in the future and may cause the actual results, performance or achievements to be materially different from those expressed or implied by such forward-looking statements, and actual results could differ materially from those currently anticipated due to a number of risks and uncertainties. These statements are not guarantees of future performance, cash reach or prospects for market share grow etc. Many of these risks and uncertainties relate to factors that are beyond each of Poolbeg's ability to control or estimate precisely, such as future market conditions, currency fluctuations, the behaviour of other market participants, the outcome of clinical trials, the actions of regulators and other factors such as Poolbeg's ability to obtain financing, changes in the political, social and regulatory framework in which Poolbeg operates or in economic, technological or consumer trends or conditions. The delivery of this presentation shall not give rise to any implication that there have been no changes to the information and opinions contained in this presentation since the time specified. Subject to obligations under the London AIM Market ("AIM") and Securities and Exchange Commission ("SEC") (as applicable and as amended from time to time), none of the Company, the Group, their affiliates and advisers and their respective directors, officers, partners, representatives, employees and agents, undertakes to publicly update or revise any such information or opinions, including without limitation, any forward-looking statement or any other statements contained in this presentation, whether as a result of new information, future events or otherwise. In giving this presentation none of the Company, the Group, their affiliates and advisers and their respective directors, officers, partners, representatives, employees and agents, undertakes any obligation to provide the recipient with access to any additional information or to update any additional information or to correct any inaccuracies in any such information which may become apparent.

Certain industry and market data contained in this presentation has been obtained from third party sources. Third party industry publications, studies and surveys generally state that the data contained therein have been obtained from sources believed to be reliable, but that there is no guarantee of the accuracy or completeness of such data. While the Company believes that each of these publications, studies or surveys has been prepared by a reputable source, the Company has not independently verified the data contained therein. In addition, certain of the industry, scientific and market data contained in this presentation comes from the Company's own internal case studies, research and estimates based on the knowledge and experience of the Company's management in the market in which it operates. While the Company believes that such research, estimates and results from its case studies are reasonable and reliable, they, and their underlying methodology and assumptions, have not been verified by any independent source for accuracy or completeness unless otherwise stated and are subject to change without notice. Risks and uncertainties affecting the Company are outlined further in the Company AIM filings.

POOLBEG PHARMA

A clinical-stage company developing POLB 001 which has the potential to transform the lives of cancer patients by delivering their treatment safely & locally creating a potential $10B market opportunity for POLB 001. Poolbeg is also developing an oral, patient-friendly obesity treatment.

Investment Case

1. **Experienced team with proven track record**
2. **High value programmes targeting critical unmet medical needs**
3. **Programmes attractive for Pharma partnering**
4. **Cash runway into 2027, funding near-term clinical value inflection points in oncology & obesity**

Partnering Focused Model

- High value programmes with strong IP
- Proof-of-concept clinical trials
- High-quality & compelling human data
- Partnering

High Value Pipeline Programmes

Multiple near-term clinical value inflection points – positioned well for partnering

Product	Modality	Indication	Preclinical	Phase 1	Phase 2	Phase 3	Key Milestones
POLB 001	p38 MAPK inhibitor	Cancer Immunotherapy-induced CRS*		**Commencing Phase 2**	**FDA Orphan Drug Designation**		▪ Trial is at an advanced stage of preparation ▪ Approved bispecific antibody secured for trial ▪ Phase 2a interim data expected summer 2026
Oral Encapsulated GLP-1	GLP-1R agonist	Obesity		AnaBio™ Technologies LTD.			▪ Progressing towards PoC trial commencement ▪ Topline PoC data expected H1 2026
AI Programmes	Novel drug discovery	Influenza		CytoReason			▪ Potential partnership
		RSV		ONETHREE BIOTECH			▪ Potential partnership

*Further life cycle opportunities, including severe influenza

AI: Artificial Intelligence; **CRS**: Cytokine Release Syndrome; **GLP-1**: Glucagon-like Receptor-1; **MAPK**: Mitogen Activated protein Kinase; **PoC**: Proof of Concept

POLB 001 – potential first approved preventative therapy for cancer immunotherapy-induced Cytokine Release Syndrome (CRS)

POLB 001 has the potential to transform the cancer immunotherapy field through the prevention of CRS thereby expanding administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals and ultimately home-based treatment

POLB 001: Executive Summary

Potential to Make Immunotherapies Safer and More Accessible

Oral p38 MAPK Inhibitor

- Selectively prevents excessive inflammation without immunosuppression
- Oral agent
- Strong patent portfolio, potential coverage out to 2044
- FDA granted Orphan Drug Designation

Strong Preclinical & Clinical Data

- Favourable safety and tolerability profile
- Potent inhibition of IL-6, TNF and other key inflammatory markers in clinical & preclinical models
- Phase 2a is at an advanced stage of preparation, interim data expected summer 2026

Significant Market Opportunity

- >US$10B market opportunity[1]
- No approved therapy for CRS prevention
- Growing number of CRS-inducing therapies in the clinic – increasing addressable market

1. Independent research by Decisive Consulting Limited. **2.** CRS score is a 0-4 system of physical observations where 0 is normal and 4 is moribund. In this context, *adequately* is defined as both not completely preventing grade 2+ CRS and potentially sufficient to support active clinical development towards a regulatory approval of a medicine. Grade 2 CRS is defined as described by Lee et al, Biol Blood Marrow Transplant . 2019 Apr;25(4):625-638. janssenscience.com & doi.org/10.1182/blood-2022-159381; CRS: Cytokine releases Syndrome. MAPK: Mitogen Activated Protein Kinase. TNF: Tumour necrosis factor, IL-6: Interleukin-6

Cancer Immunotherapy-Induced CRS

Effective preventative therapy represents a >US$10B market opportunity

Cytokine Release Syndrome

- A severe, potentially life-threatening side effect
- >70%[1] of patients undergoing CAR T / BsAb treatment can be affected[1]

Impact of CRS

- Treatment restricted to specialist cancer centres
- Extended hospitalisation & high consumption of healthcare resources

Unmet Need

- No approved therapies for prevention
- Approved options for CRS management (tocilizumab) have not adequately[2] prevented Grade 2+ CRS

"POLB 001 could make treatment safe enough to extend bispecifics to a much wider patient population."

Professor Gareth Morgan, NYU Langone, US

1. Average rate from Summary of Product Characteristics (SmPCs) for Yescarta, Tecartus, Abecma, Kymriah, Carvykti, Breyanzi, Elrexfio, Columvi, Epkinly, Tecvayli and Talvey; **2.** In this context, *adequately* is defined as both not completely preventing grade 2+ CRS and potentially sufficient to support active clinical development towards a regulatory approval of a medicine. Grade 2 CRS is defined as described by Lee et al, Biol Blood Marrow Transplant . 2019 Apr;25(4):625-638. janssenscience.com & doi.org/10.1182/blood-2022-159381; **CAR T:** Chimeric Antigen receptor T cell; **BsAb**: Bispecific Antibody; **CRS**: Cytokine Release Syndrome.

The POLB 001 Trial is Designed to be Very Short with Rapid Results Generated

The trial only monitors patients for 1-2 months and therefore we are not waiting 1-2 years for the trial to complete

- Typical oncology trials tend to take years to complete
- Our POLB 001 trial only monitors if the patient gets CRS or not
- Open label – we see results almost immediately
- Single arm - every patient gets our drug i.e. no placebo



Inhibition of p38 MAPK – A Differentiated Solution For CRS

Mechanism of action



- p38 MAPK acts as a gatekeeper to inflammatory responses
- Inhibition causes a potent decrease of a wide range of pro-inflammatory cytokines without ablating the immune system

POLB 001: Broader Cytokine Inhibition Profile vs Competition

	TNF	IL-1α	IL-1β	IL-2	IL-3	IL-4	IL-5	IL-6	IL-8	IL-10	IL-12	IL-13	IL-15	IL-17	IL-20	IL-21	IL-22	IL-23	IL-27	IP-10	CCL2	CXCL1	COX-2	CSF1	G-CSF	GM-CSF	iNOS	MIP1α	MIP1β	VEGF	uPAR	PGE2	IFNα	IFNβ	IFNγ
POLB 001	●	●	●	●	●	●	●	●	●	●	●	●		●	●			●		●	●	●	●	●		●	●	●	●	●	●	●			●
Tocilizumab						●		●		●				●		●																			●
Dexamethasone	●		●	●	●			●	●	●				●							●														●
Itacitinib	●			●		●		●		●		●	●			●	●								●								●	●	●

● Direct pathway effect ● Secondary consequence

POLB 001 has a novel and differentiated mechanism of action*

*The table presents a select overview of certain cytokines and certain comparative drugs and is not intended to depict the full pharmacological profile of each drug.

Table references: Frevel et al, Mol Cell Biol. 2003 Jan;23(2):425–436. Tiedje et al, J Interferon Cytokine Res. 2014 Apr;34(4):220-32. Ogilvie et al, J Immunol (2005) 174 (2): 953–961. Dodeller et al, Eur J Immunol . 2005 Dec;35(12):3631-42. Vockerodt et al, Int J Cancer . 2005 Apr 20;114(4):598-605. Khaber. J Leukoc Biol. 2007 Mar 30;81(6):1335–1344. noubade et al. Blood. 2011 Jul 25;118(12):3290–3300. Yanagawa and Onoé. mmunology. 2006 Apr;117(4):526–535. Johansen et al. Br J Dermatol . 2010 Dec;163(6):1194-204. Guan et al, J Biol Chem . 1998 May 22;273(21):12901-8. Lahti et al, BMC Pharmacol. 2006 Feb 21;6:5. Gonsalves et al, J Immunol . 2010 Nov 15;185(10):6253-64. Grebenciucova and VanHaerents, Front Immunol . 2023 Sep 28:14:125553. Hudson et al, Nat Commun. 2018 Apr 6;9(1):1337. Menson et al, Am J Physiol Lung Cell Mol Physiol . 2020 Oct 1;319(4):L693-L709. Franchimont et al, Regul Pept . 1998 Jan 2;73(1):59-65. Spinelli et al, Rheumatology (Oxford). 2021 May 5;60(Suppl 2):ii3–ii10. yarilina et al, Arthritis Rheum. 2012 Dec;64(12):3856–3866. Johnson et al, Bioorg Med Chem Lett . 2019 Jun 15;29(12):1522-1531.

Phase 1b LPS Human Challenge – Potent Inhibition of Excessive Inflammation

Positive data supports the potential of POLB 001 to effectively prevent CRS

ASH '23

Phase 1b LPS Human Challenge Trial

- Excellent safety & tolerability profile
- Potent target inhibition confirmed
- Clear dose response relationship observed
- Major reduction of key inflammatory markers

IL-6 Levels



57.4% and 63.5% decrease for 70 mg & 150 mg doses respectively (p = 0.0002)

IL-8 levels



IL-8 reduction of 80.7% and 76.7% seen for 70 mg and 150 mg doses respectively ($p < 0.0001$)

● Placebo ■ 30 mg POLB 001 ▲ 70 mg POLB 001 ▼ 150 mg POLB 001

Potential to effectively prevent CRS while preserving key immune system functionality

Trial design: Single site, randomized placebo controlled LPS challenge trial. Healthy males administered BID oral POLB 001 or vehicle only control & challenged with local dermal LPS on day 4 and systemic IV LPS on day 6 to evaluate effect of POLB 001 on local and systemic inflammatory responses respectively. n=9 per group, all endpoints were exploratory. **BID**: twice daily; **CRS**: Cytokine Release Syndrome; **ID**: Intradermal; **IV**: Intravenous; **IL-6**: Interleukin-6.

Upcoming POLB 001 First-in-Patient Phase 2a Trial

Supply of approved bispecific antibody secured at no cost to Poolbeg

TOPICAL - Trial of Prevention of ImmunoCytokine Adverse events in Myeloma	
Chief Investigator	Dr Emma Searle, MBChB MA MRCP FRCPath PhD
Trial run by	Accelerating Clinical Trials (ACT) - specialist blood cancer trials organisation
Sites	The Christie NHS Foundation Trust and other leading UK specialist cancer centres
Objective	To investigate the safety and efficacy of POLB 001, in particular its ability to reduce incidence of CRS in patients receiving an approved bispecific antibody
Number of subjects	c. 30
Patient population	Relapsed/refractory multiple myeloma patients

"I have seen first-hand the challenges that CRS presents to the delivery of cancer immunotherapies, requiring many of our patients to be hospitalised for treatment. These transformative therapies will continue to be restricted until there is a way to administer them more safely. POLB 001 holds great promise in tackling this issue; potentially leading to improved patient wellbeing, reducing the strain on healthcare systems while making these treatments more accessible to a broader patient population."

Dr Emma Searle, Consultant Haematologist

CRS: Cytokine Release Syndrome

POLB 001 Phase 2a Trial

Trial designed to produce rapid & compelling data for the effectiveness of POLB 001 to prevent CRS

Proposed Trial Design



2x Daily Oral	Single Arm	N = ~30	Approved bispecific	Open Label

Key Endpoints

- Incidence of CRS
- Severity of CRS
- Confirm safety & pharmacokinetics
- CRS management / tocilizumab usage

Milestones

- ✓ Supply of approved bispecific antibody secured at no cost to Poolbeg
- ✓ Supply of GMP grade POLB 001 ready
- ✓ Trial at an advanced stage of preparation
- ❑ Interim data expected summer 2026

Actively exploring partnering for further development

BsAb: Bispecific antibody; **CRS**: Cytokine Release Syndrome; **GMP:** Good manufacturing practice; **Tx**: Treatment.
*Bispecific antibody dosing days estimated for demonstrative purposes only and may vary.

POLB 001 Programme is Supported by Leading Organisations

UK's leading oncology sites participating on trial

POLB 001 Phase 2a CRO

ACT | Accelerating clinical trials for patients

- A specialised trials delivery organisation dedicated to blood cancers. it is borne from, and embedded in, the leading UK haematology community
- Equipped to provide registrational standard trials and accelerated delivery

Top Sites on POLB 001 Phase 2a

NHS The Christie NHS Foundation Trust

- The Christie plus three other leading UK sites selected to rapidly deliver the trial – new sites to be announced soon
- Significant interest allowed selection of sites with excellent clinical trial units and high volume of patients
- Investigators highly motivated to deliver interim data by summer 2026

Significant Market Opportunity in a Rapidly Growing Field

CRS is a major issue and rate limiting in delivering cancer immunotherapies

Potential Benefits of FDA Orphan Drug Designation

Granted May 2025

- 7 years U.S. marketing exclusivity from approval
- Waiver of New Drug Application fees (value >US$4m)
- Earlier access to Special Protocol Assessment to agree on pivotal trial designs
- Tax credits for qualified clinical trials

BsAb & CAR T Market Expected to Grow Exponentially



Need for effective CRS management is driven by rapid growth of CRS-inducing cancer immunotherapies

POLB 001 – potential first approved preventative therapy for cancer immunotherapy-induced CRS

1. Grand View Research. CAR T-Cell Therapy Market Analysis 2023-2030. **2.** Grand View Research. Bispecific Antibodies Market Size, Share & Trends Analysis Report. **3.** Datamonitor Healthcare. Forecast: Diffuse Large B-Cell Lymphoma and Multiple Myeloma, 2023.
BsAb: Bispecific Antibody; **CAR T**: Chimeric Antigen Receptor T cell therapy; **CRS**: Cytokine Release Syndrome.

Prevention of CRS by POLB 001 May Transform Cancer Immunotherapies

Potential to greatly enhance uptake and access to BsAb and CAR-T therapies



"If there was a therapy that was orally delivered, a whole lot of infrastructure requirement falls away"

Prof Martin Kaiser, Royal Marsden, UK

"The development of an oral CRS preventive therapy will mean no or shorter hospital stays."

Myeloma specialist, FR

1. Datamonitor Healthcare. Forecast: Diffuse Large B-Cell Lymphoma and Multiple Myeloma, 2023. **2.** Independent research by Decisive Consulting Limited.
*CRS prevention may contribute to bottleneck removal. Other issues, such as manufacturing, supply and other adverse events, may also present barriers to wider uptake.

Prevention of CRS by POLB 001 May Transform Cancer Immunotherapies

Potential to greatly enhance uptake and access to BsAb and CAR-T therapies

~500,000 Patients

Eligible **bispecific antibody / CAR T** patients in US & EU5 for DLBCL and MM alone far exceeds treatment capacity[1]

An effective CRS preventative therapy may remove the bottleneck

>US$10B[2]

Market opportunity

"If there was a therapy that was orally delivered, a whole lot of infrastructure requirement falls away"

Prof Martin Kaiser, Royal Marsden, UK

"The development of an oral CRS preventive therapy will mean no or shorter hospital stays."

Myeloma specialist, FR

1. Datamonitor Healthcare. Forecast: Diffuse Large B-Cell Lymphoma and Multiple Myeloma, 2023. **2.** Independent research by Decisive Consulting Limited.
*CRS prevention may contribute to bottleneck removal. Other issues, such as manufacturing, supply and other adverse events, may also present barriers to wider uptake.

POLB 001: Oncology CRS - Regulatory Exclusivity / Patent Timeline



†Portfolio includes a patent covering use of POLB 001 for hypercytokinemia/CRS that was granted by the US Patent Office in April 2024, with a latest expiry date in Dec 2038 excl. extensions.
*Orphan exclusivity subject to grant of Orphan Designation by EMA
** Subject to any extensions: patent term adjustment (PTA) and/or patent term extension (PTE)
Note: Commencement date for market exclusivity and Orphan exclusivity is for demonstrational purposes only and is not intended to reflect actual, anticipated or proposed dates by the Company

Partnering Focussed

Effective preventative therapy represents a >US$10B market opportunity

Pharma Seeking Assets

- Growing number of CRS-inducing cancer immunotherapies in the clinic
- Some of the steepest “patent cliffs” approaching - drugs expected to generate >$300B in total revenue over the next six years will lose their patent protection by 2030

Key Conference Attendance

- European Society Medical Oncology, Oct 25
- BIO Europe, Nov 25
- London Life Science Week, Nov 25
- ASH Annual Meeting, Dec 25
- JP Morgan Healthcare Conference Week, Jan 26

Discussions Ongoing

- Approved bispecific secured from Top 5 Global Pharma
- Discussions with key mid-sized and Big Pharma
- NDAs in place – individual data to be shared on a regular basis

We are excited for what’s to come in 2026 – a catalyst-rich period

GLP-1 Programme

Oral encapsulated GLP-1R agonist targeting the obesity market

Oral GLP-1R Agonist Targeting the Obesity Market

Proof of concept trial topline data expected H1 2026

- **Proprietary** delivery technology with leading expert in obesity & metabolic medicine
- Microencapsulated GLP-1 with **targeted gut delivery** with potential to improve convenience and bioavailability
- Potential to overcome oral delivery challenges of peptide-based biologicals

Trial Investigator: Prof Carel le Roux

Site: University of Ulster

Objective: Demonstrate GLP-1 uptake

Endpoints: Safety, tolerability & PK

N = Up to 20

Population: Obese subjects

"This trial is designed to generate impactful data that demonstrates our ability to safely and efficiently deliver an oral GLP-1R agonist using a validated technology." **Prof Carel le Roux**

Successful results from the trial may support partnering & multiple opportunities for value creation

GLP-1: Glucagon like-peptide-1; **PK**: Pharmacokinetics.

Significant Potential for Oral GLP-1 to Claim Market Share

Major shortcomings within currently approved treatment options

Large Growing Market

US$347B

Economic impact of obesity on US businesses & employees 2023[1]

US$150B

GLP-1R agonist market projection by 2031[2]

42%

US population effected by Obesity[3]

Shortcomings of Existing Options

c.99%

API wasted in current oral options[4]

>45%

Patients **discontinue** GLP-1s within 1 year[5]

64%

Patients cite **nausea** for discontinuation[6]

45%

Patients cite **vomiting** for discontinuation[6]

56%

Discontinuations would **prefer oral** alternatives[6]

AnaBio's Encapsulation Centre of Excellence

- 2,000m^2 state of the art manufacturing facility
- FFSC2200, FDA accredited
- Commercialises encapsulated bioactives in food and beverage applications

1. Global Data, Assessing the Economic Impact of Obesity and Overweight on Employers, Feb 2024. **2.** The Economist, March 2023. **3.** Stierman B, Afful J, Carroll MD, et al. National Health and Nutrition Examination Survey 2017–March 2020 prepandemic data files development of files and prevalence estimates for selected health outcomes. Natl Health Stat Report. 2021;158. **4.** PMID: 26921819 **5**. PMID: 35101924. 6. PMID: 29033597.
API: Active Pharmaceutical Ingredient; **GLP-1**: Glucagon like-peptide-1.

Strategic & Financial Highlights

Funded through key clinical milestones in high interest areas

Strategic & Financial Highlights

Clear plan to deliver shareholder returns

- **Partnering Focused Model**: Cost-effective trials designed to produce high-quality human data and accelerate partnering discussions
- **Proven Team**: Expertise in trial execution and deal-making – CEO Jeremy Skillington was instrumental in Inflazome's US$450M+ sale to Roche in 2020
- **Well Capitalised**: Cash balance of £10.0M (30 June 2025), including £4.865M gross proceeds raised as part of an oversubscribed and upsized fundraise, giving a runway into 2027
- **Multiple Potential Value Catalysts Ahead**:
  - POLB 001 Phase 2a trial initiation, interim analysis and topline data
  - Oral GLP-1 proof-of-concept trial initiation and topline data readout

Well-capitalised and entering a catalyst-rich period

Investment Highlights

Experienced team with proven track record

High value programmes targeting critical unmet medical needs

Programmes attractive for **Pharma partnering**

Cash runway into 2027, funding near-term clinical value inflection points in oncology & obesity

AIM: POLB

Appendix

Leadership Team with Record of Delivering Value

Track record of building successful life-science companies

Cathal Friel

Executive Chairman

hVIVO formerly Open Orphan plc

AMRYT PHARMA

Raglan Capital

Jeremy Skillington PhD

Chief Executive Officer

INFLAZOME Targeted Therapies for Inflammatory Diseases

Genentech A Member of the Roche Group

ETHRIS

Ian O'Connell

Chief Financial Officer

hVIVO formerly Open Orphan plc

AMRYT PHARMA

Deloitte.

Board Includes Leading Non-Executive Directors

A long history of success in the life sciences industry

Prof Luke O'Neill

Non-Executive Director

Trinity College Dublin, The University of Dublin; INFLAZOME Targeted Therapies for Inflammatory Diseases; GSK

- ✓ Co-Founder Inflazome which was acquired by Roche in 2020 for €380M + milestones
- ✓ Previously scientific advisory board member of GSK & Pfizer

Eddie Gibson

Non-Executive Director

WICKENSTONES; Bristol Myers Squibb; AVEO ONCOLOGY

- ✓ Market access expert
- ✓ Supported numerous drug companies secure pricing and reimbursement

Prof Brendan Buckley

Non-Executive Director

EUROPEAN MEDICINES AGENCY SCIENCE MEDICINES HEALTH; UNIVERSITY OF OXFORD; ICON

- ✓ Former Chief Medical Officer at ICON plc
- ✓ Former member of Committee for Orphan Medicinal Products & Scientific Advisory Group for Diabetes and Endocrinology at the EMA

An Oral p38 MAPK Inhibitor That Selectively Targets Key Inflammatory Path Without Broad Immunosuppression

Phase 2 ready asset with a comprehensive pre-clinical and clinical data package

Favourable Safety and Tolerability Profile

- 97 subjects dosed during Phase I FIH and LPS Challenge studies
- No SAEs or discontinuations due to AEs, all were of mild intensity
- No clinically meaningful findings in clinical laboratory test results, vital signs or ECG
- Favourable safety & tolerability profile

Designed to Prevent Immunotherapy-Induced CRS

- Suitable for at-home dosing (used in LPS Challenge Trial)
- Hepatic metabolism and biliary excretion profile favourable for multiple myeloma and renally impaired populations
- BID oral regimen designed to provide targeted protection during CRS risk period
- Half-life of 7-14 hours provides adequate exposure and avoids excessive exposure beyond periods of CRS risk

AE: adverse event; **FIH**: First in human; **SAE**: Serious adverse events; **ECG**: Electrocardiogram.

Potent and Selective Inhibition of p38 MAPK Signalling

Effective target engagement demonstrated in LPS human challenge trial

Levels of Phosphorylated p38 MAPK in Circulating Monocytes



- POLB 001 was **widely distributed**
- POLB 001 **inhibited p38 MAPK activation**, direct measurement of activation
- POLB 001 i**nhibited in vivo and ex vivo responses** to LPS-induced TNF-α, indirect measurement of p38 MAPK inhibition

Blood samples were taken before and after administration of intravenous LPS. Peripheral blood samples were analysed by flow cytometry. Monocytes were gated by FSC, SSC and CD14+. Data is presented as mean MFI values of phospho-p38 +/- SEM.

Reduced Key Inflammatory Cytokines Following LPS Challenge

Dose dependent reductions, without ablation of immune function

TNF-α



IL-8



Placebo ■ 30 mg POLB 001 ▲ 70 mg POLB 001 ▼ 150 mg POLB 001

TNF-α reduction of **73.5% and 56.2%** seen for **70 mg and 150 mg doses respectively** (p = 0.0003)

IL-8 reduction of **80.7% and 76.7%** seen for **70 mg and 150 mg doses respectively** (p < 0.0001)

TNF-α and IL-8 levels decreased between 56-81% in subjects treated with 70 mg or 150 mg POLB 001 twice daily

Reduced Key Indicators of LPS-Induced Systemic Inflammation

The reduction of systemic cytokines align with improvement in clinically meaningful endpoints

Mean Body Temperature



Heart Rate Rise (bpm)



C-Reactive Protein (CRP)



Placebo | 30 mg POLB 001 | 70 mg POLB 001 | 150 mg POLB 001

No significant effect on body temperature with a trend towards reduction compared to placebo

Suppressed increase in heart rate following IV LPS administration

CRP level reduction of **33.1% and 33.3%** seen for **70 mg and 150 mg** doses respectively

CRS Preventative Therapy: >US$10B US Market Opportunity

Significant opportunity exists for POLB 001 as CRS preventative for BsAb and CAR T treatment3

1st, 2nd and 3rd line+ MM and DLBCL patients in the US and EU5, receive CAR T and bispecific antibody therapy[1]

An effective preventative therapy for CRS could **enable outpatient administration and broader uptake** of cancer immunotherapies[2]

Potential across additional haematological malignancies, solid tumours and new areas like severe influenza

Addressable MM and DLBCL population by 2030 in the US and EU5



n = ~500,000 patients[1]

Estimate encompasses solely MM & DLBCL due to rapid advancements in bispecific antibody & CAR T treatment for these indications. Conservative price estimate versus market peers

1. Datamonitor Healthcare. Forecast: Diffuse Large B-Cell Lymphoma and Multiple Myeloma, 2023. **2.** Hansen DK et al., Cancers (Basel). 2023. 7;15(24):5746. **3.** Independent research by Decisive Consulting Limited.
BsAb: Bispecific antibody; **CAR T**: Chimeric Antigen Receptor T cell therapy; **CRS**: Cytokine Release Syndrome; **MM**: Multiple Myeloma; **DLBCL**: Diffuse Large B-Cell Lymphoma.

Grades & Severity of CRS

CRS is a common adverse event following CAR T and bispecific antibody treatment

CRS Parameter[1]	Grade 1	Grade 2	Grade 3	Grade 4
Fever	Fever ≥ 38°C (not attributable to any other cause). In patients who have CRS then receive antipyretics or anti-cytokine therapy such as tocilizumab or steroids, fever is no longer required to grade subsequent CRS severity. In this case, CRS grading is driven by hypotension and/or hypoxia			
Hypotension*	None	Not requiring vasopressors	Requiring a vasopressor ± vasopressin	Requiring multiple vasopressors (excluding vasopressin)
Hypoxia*	None	Requiring low-flow oxygen (≤6 L/min)	Requiring high-flow oxygen (>6 L/min)	Requiring oxygen by positive pressure

*CRS severity is determined if either hypotension or hypoxia criteria is achieved for a given grade

1. Ayuketang FA, Jäger U. Management of Cytokine Release Syndrome (CRS) and HLH. 2022. The EBMT/EHA CAR T Cell Handbook. Chapter 26.

POLB 001: Flu & Hypercytokinemia - Regulatory Exclusivity / Patent Timeline



†Portfolio includes a patent covering use of POLB 001 for hypercytokinemia/CRS that was granted by the US Patent Office in April 2024, with a latest expiry date in Dec 2038 excl. extensions.
*Orphan exclusivity subject to grant of Orphan Drug designation and Orphan Designation by FDA and EMA respectively
** Subject to any extensions: patent term adjustment (PTA) and/or patent term extension (PTE)
Note: Commencement date for market exclusivity and Orphan exclusivity is for demonstrational purposes only and is not intended to reflect actual, anticipated or proposed dates by the Company

Oral Encapsulated GLP-1 - Regulatory Exclusivity / Patent Timeline



*Subject to any extensions, such as US patent term adjustment (PTA).
**Unfiled; filing date TBC.
† Extent of coverage of specific products in development is TBC.

Human Challenge Data has Attracted Expert AI Collaborators

POOLBEG PHARMA

CytoReason

Novel influenza drug targets successfully identified and prioritised

CytoReason's Partners

Pfizer · Roche · sanofi · MERCK

"Human challenge data is extremely rare, and the number of such datasets is limited. None of them have the same richness as this dataset"

Prof Shai Shen-Orr, Co-Founder & Chief Scientist

ONETHREE BIOTECH

Successfully identified drugs with potential to combat RSV with existing clinical data in other indications

OneThree Biotech's Partners

AstraZeneca · Boehringer Ingelheim · LEO · Stanford University

"One thing I was excited about was the uniqueness and quality of the data. AI is only as powerful as the data you bring in"

Neel Madhukar, PhD, CEO

Progressing potential partnerships

AI: Artificial Intelligence; **RSV**: Respiratory Syncytial Virus.

POLB 001 has the potential to transform the cancer immunotherapy field through the prevention of CRS thereby expanding administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals

Stay in touch

Listed on the London Stock Exchange
Ticker: POLB

Register for RNS alerts